High rates of recurrence of DFUs and reintervention for chronic limb-threatening ischemia impose a notable, unrecognized ...

Diabetes is a significant predictor of tumor recurrence after potentially curative therapy for hepatocellular carcinoma in patients with nonviral hepatitis.

Diabetes mellitus (DM) appears to be an independent predictor of disease recurrence and progression among patients with non-muscle invasive bladder cancer (NMIBC), according to investigators.

In patients with type 2 diabetes, GLP-1 agonist therapy is associated with decreased risk for AF recurrence following ablation for AF.

Hepatocellular carcinoma, a type of liver cancer associated with hepatitis infections, is known to have a high recurrence rate after cancer removal.